-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 16, what new things in the pharmaceutical industry are worth looking at? The author made a brief summary based on the announcements disclosed by major pharmaceutical companies
.
|A quick overview of the content of this issue| ●Hansen Pharma’s clinical trial of antifungal drugs approved ●Shenzhou Cell: Adalimumab injection drug registration application accepted ●Shanghai Pharmaceuticals: The company does not implement consolidated control over Shanghai Pharmaceutical Kangsino ● Deck Pharma-B: Repurchase of 200,000 shares involving 2.
08 million yuan ● WuXi Biologics responds to a sharp drop in stock price: plans to repurchase no more than US$500 million Pharmaceuticals: Clinical trials of antifungal drugs were approved.
On December 16, Hansen Pharmaceuticals announced that Ibrexafungerp tablets have been approved and issued by the China National Medical Products Administration
.
The group will carry out a phase 3 clinical trial for VVC in China
.
It is understood that Ibrexafungerp is an antifungal drug with a new mechanism of action
.
02 Shenzhou Cell: Adalimumab injection drug registration application has been accepted.
Shenzhou Cell issued an announcement stating that the holding subsidiary Shenzhou Cell Engineering Co.
, Ltd.
received the company’s research product adalimumab injection from the State Food and Drug Administration.
The "Notice of Acceptance" of the application for the registration and marketing authorization of the production drug, the drug registration application was accepted
.
According to the announcement, the above-mentioned products are adalimumab biosimilars independently developed by Shenzhou Cell, which are intended to be used for the treatment of immune system diseases such as psoriasis, rheumatoid arthritis and ankylosing spondylitis
.
The company has a complete biopharmaceutical production technology platform, and has successfully completed product trial production on a commercial-scale production line
.
03 Shanghai Pharmaceuticals: The company announced that Shanghai Pharmaceuticals will not implement consolidated control over Shanghai Pharmaceuticals Kangsino.
Recently, a number of media have realized the quantity of recombinant new coronavirus vaccines (type 5 adenovirus vectors) produced by Shanghais Pharmaceuticals Kangsino Biopharmaceutical Co.
, Ltd.
The production and offline related matters were reported
.
The company made an explanation on the relevant situation: As of now, Shanghai Pharmaceutical Kangsino has not had a significant impact on the company’s operating results, and the company does not implement consolidated control over Shanghai Pharmaceuticals Kangsino
.
04 Deck Pharma-B: Repurchase of 200,000 shares involving a capital of 2.
08 million Deck Pharma-B announced that it will repurchase 200,000 shares on December 15, 2021.
The repurchase price per share ranges from 10.
18 Hong Kong dollars to 10.
54 Hong Kong dollars.
Involving 2.
08 million yuan
.
So far this year (since the passing of the ordinary resolution), the cumulative number of securities repurchased is 4,610,500 shares, accounting for 0.
687% of the number of shares issued at the time of passing the ordinary resolution
.
05 WuXi Biologics responded to the sharp drop in its stock price: WuXi Biologics plans to repurchase no more than US$500 million in an announcement on the Hong Kong Stock Exchange in the morning, stating that the company has learned that the company’s shares had unusual stock prices and trading volume on December 15, 2021 Volatility
.
As of the date of this announcement, the company is not aware of any changes in the regulatory system that may have a significant adverse impact on business operations
.
The company will continue to work hard to empower its partners and is confident in the continued rapid growth in the future
.
In addition, the board of directors has resolved to use the repurchase authorization to repurchase shares on the open market from time to time for a total price of not more than US$500 million
.
06 On the first day of listing on BeiGene Science and Technology Innovation Board, it fell sharply.
On December 15, BeiGene was officially listed on the Science and Technology Innovation Board and became a pharmaceutical company listed on the Nasdaq, Hong Kong Stock Exchange and Shanghai Stock Exchange
.
In this IPO, BeiGene publicly issued 115 million new shares, raising more than 20 billion yuan.
However, on the first day of the IPO, it caught up with the collective diving in the biomedical sector.
BeiGene broke the market and fell 8%, and then the stock price continued to fall.
As of the close of the day, it was reported at 160.
98 yuan per share, with a total market value of 214.
9 billion yuan
.
.
|A quick overview of the content of this issue| ●Hansen Pharma’s clinical trial of antifungal drugs approved ●Shenzhou Cell: Adalimumab injection drug registration application accepted ●Shanghai Pharmaceuticals: The company does not implement consolidated control over Shanghai Pharmaceutical Kangsino ● Deck Pharma-B: Repurchase of 200,000 shares involving 2.
08 million yuan ● WuXi Biologics responds to a sharp drop in stock price: plans to repurchase no more than US$500 million Pharmaceuticals: Clinical trials of antifungal drugs were approved.
On December 16, Hansen Pharmaceuticals announced that Ibrexafungerp tablets have been approved and issued by the China National Medical Products Administration
.
The group will carry out a phase 3 clinical trial for VVC in China
.
It is understood that Ibrexafungerp is an antifungal drug with a new mechanism of action
.
02 Shenzhou Cell: Adalimumab injection drug registration application has been accepted.
Shenzhou Cell issued an announcement stating that the holding subsidiary Shenzhou Cell Engineering Co.
, Ltd.
received the company’s research product adalimumab injection from the State Food and Drug Administration.
The "Notice of Acceptance" of the application for the registration and marketing authorization of the production drug, the drug registration application was accepted
.
According to the announcement, the above-mentioned products are adalimumab biosimilars independently developed by Shenzhou Cell, which are intended to be used for the treatment of immune system diseases such as psoriasis, rheumatoid arthritis and ankylosing spondylitis
.
The company has a complete biopharmaceutical production technology platform, and has successfully completed product trial production on a commercial-scale production line
.
03 Shanghai Pharmaceuticals: The company announced that Shanghai Pharmaceuticals will not implement consolidated control over Shanghai Pharmaceuticals Kangsino.
Recently, a number of media have realized the quantity of recombinant new coronavirus vaccines (type 5 adenovirus vectors) produced by Shanghais Pharmaceuticals Kangsino Biopharmaceutical Co.
, Ltd.
The production and offline related matters were reported
.
The company made an explanation on the relevant situation: As of now, Shanghai Pharmaceutical Kangsino has not had a significant impact on the company’s operating results, and the company does not implement consolidated control over Shanghai Pharmaceuticals Kangsino
.
04 Deck Pharma-B: Repurchase of 200,000 shares involving a capital of 2.
08 million Deck Pharma-B announced that it will repurchase 200,000 shares on December 15, 2021.
The repurchase price per share ranges from 10.
18 Hong Kong dollars to 10.
54 Hong Kong dollars.
Involving 2.
08 million yuan
.
So far this year (since the passing of the ordinary resolution), the cumulative number of securities repurchased is 4,610,500 shares, accounting for 0.
687% of the number of shares issued at the time of passing the ordinary resolution
.
05 WuXi Biologics responded to the sharp drop in its stock price: WuXi Biologics plans to repurchase no more than US$500 million in an announcement on the Hong Kong Stock Exchange in the morning, stating that the company has learned that the company’s shares had unusual stock prices and trading volume on December 15, 2021 Volatility
.
As of the date of this announcement, the company is not aware of any changes in the regulatory system that may have a significant adverse impact on business operations
.
The company will continue to work hard to empower its partners and is confident in the continued rapid growth in the future
.
In addition, the board of directors has resolved to use the repurchase authorization to repurchase shares on the open market from time to time for a total price of not more than US$500 million
.
06 On the first day of listing on BeiGene Science and Technology Innovation Board, it fell sharply.
On December 15, BeiGene was officially listed on the Science and Technology Innovation Board and became a pharmaceutical company listed on the Nasdaq, Hong Kong Stock Exchange and Shanghai Stock Exchange
.
In this IPO, BeiGene publicly issued 115 million new shares, raising more than 20 billion yuan.
However, on the first day of the IPO, it caught up with the collective diving in the biomedical sector.
BeiGene broke the market and fell 8%, and then the stock price continued to fall.
As of the close of the day, it was reported at 160.
98 yuan per share, with a total market value of 214.
9 billion yuan
.
